1. Cheng Q, Huang J, Xu L, Li Y, Li H, Shen Y, et al. Analysis of time-course, dose -effect, and influencing factors of antidepressants in the treatment of acute adult patients with major depression. J Psychopharmacol. 2020;23:76–87.
2. Rupprecht R, Rammes G, Eser D, Baghai TC, Schüle C, Nothdurfter C, et al. Translocator protein (18 kDa) as target for anxiolytics without benzodiazepine-like side effects. Science. 2009;325:490–3.
3. Edinoff AN, Nix CA, Hollier J, Sagera CE, Delacroix MB, Abubkar T, et al. Benzodiazepines: uses, dangers, and clinical considerations. Neuro Int. 2021;13:594–607.
4. Furukawa TA, Streiner DL, Young LT. Antidepressant plus benzodiazepine for major depression. Cochrane Database Syst Rev. 2001;2:CD001026.
5. Ogawa Y, Takeshima N, Tajika A, Watanabe N, Streiner D, Fururkawa TA. Antidepressants plus benzodiazepines for adults with major depression. Cochrane Database Syst Rev. 2019;3:CD001026.